Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-rhBMP-2 Containing Artificial Bone Graft Administration

Int J Mol Sci. 2021 Nov 26;22(23):12823. doi: 10.3390/ijms222312823.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is related to impaired bone healing conditions in the maxillomandibular bone region as a complication of bisphosphonate intake. Although there are several hypotheses for the onset of MRONJ symptoms, one of the possible causes is the inhibition of bone turnover and blood supply leading to bone necrosis. The optimal treatment strategy for MRONJ has not been established either. BMP-2, a member of the TGF-β superfamily, is well known for regulating bone remodeling and homeostasis prenatally and postnatally. Therefore, the objectives of this study were to evaluate whether cyclophosphamide/zoledronate (CY/ZA) induces necrosis of the bone surrounding the tooth extraction socket, and to examine the therapeutic potential of BMP-2 in combination with the hard osteoinductive biomaterial, β-tricalcium phosphate (β-TCP), in the prevention and treatment of alveolar bone loss around the tooth extraction socket in MRONJ-like mice models. First, CY/ZA was intraperitoneally administered for three weeks, and alveolar bone necrosis was evaluated before and after tooth extraction. Next, the effect of BMP-2/β-TCP was investigated in both MRONJ-like prevention and treatment models. In the prevention model, CY/ZA was continuously administered for four weeks after BMP-2/β-TCP transplantation. In the treatment model, CY/ZA administration was suspended after transplantation of BMP-2/β-TCP. The results showed that CY/ZA induced a significant decrease in the number of empty lacunae, a sign of bone necrosis, in the alveolar bone around the tooth extraction socket after tooth extraction. Histological analysis showed a significant decrease in the necrotic alveolar bone around tooth extraction sockets in the BMP-2/β-TCP transplantation group compared to the non-transplanted control group in both MRONJ-like prevention and treatment models. However, bone mineral density, determined by micro-CT analysis, was significantly higher in the BMP-2/β-TCP transplanted group than in the control group in the prevention model only. These results clarified that alveolar bone necrosis around tooth extraction sockets can be induced after surgical intervention under CY/ZA administration. In addition, transplantation of BMP-2/β-TCP reduced the necrotic alveolar bone around the tooth extraction socket. Therefore, a combination of BMP-2/β-TCP could be an alternative approach for both prevention and treatment of MRONJ-like symptoms.

Keywords: BMP-2; bone formation; bone necrosis; medication-related osteonecrosis of the jaw; β-tricalcium phosphate.

MeSH terms

  • Alveolar Bone Loss / etiology
  • Alveolar Bone Loss / metabolism
  • Alveolar Bone Loss / pathology
  • Alveolar Bone Loss / therapy
  • Animals
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / metabolism
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / pathology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / therapy*
  • Bone Density Conservation Agents / toxicity
  • Bone Morphogenetic Protein 2 / administration & dosage*
  • Bone Transplantation / methods*
  • Calcium Phosphates / administration & dosage*
  • Calcium Phosphates / pharmacology
  • Cyclophosphamide / toxicity*
  • Diphosphonates / toxicity
  • Disease Models, Animal
  • Female
  • Immunosuppressive Agents / toxicity
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Proteins / administration & dosage
  • Tooth Extraction / adverse effects*
  • Transforming Growth Factor beta / administration & dosage*
  • Wound Healing
  • Zoledronic Acid / toxicity*

Substances

  • Bone Density Conservation Agents
  • Bone Morphogenetic Protein 2
  • Calcium Phosphates
  • Diphosphonates
  • Immunosuppressive Agents
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • beta-tricalcium phosphate
  • recombinant human bone morphogenetic protein-2
  • Zoledronic Acid
  • Cyclophosphamide